We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $1.85M
1-Year Est. Return 176.16%
This Fund
S&P 500
This Quarter Est. Return
-5.66%
1 Year Est. Return
+176.16%
3 Year Est. Return
+511.75%
5 Year Est. Return
+854.95%
10 Year Est. Return
+8,566.11%
AUM
$108M
AUM Growth
-$175M
Cap. Flow
+$9.09M
Cap. Flow %
8.4%
Top 10 Hldgs %
92.43%
Holding
31
New
6
Increased
13
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
SBBP
Strongbridge Biopharma plc.
SBBP
+$4.59M
2
MTEM
Molecular Templates, Inc.
MTEM
+$2.79M
3
SCYX icon
SCYNEXIS
SCYX
+$2.02M
4
KALA icon
KALA BIO
KALA
+$640K
5
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$489K

Top Sells

Rank Stock Value
1
LITS
Lite Strategy Inc
LITS
+$2.95M
2
ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
+$763K
3
BBDC icon
Barings BDC
BBDC
+$302K
4
GARS
Garrison Capital Inc.
GARS
+$50.5K
5
MRKR icon
Marker Therapeutics
MRKR
+$26.9K

Sector Composition

Rank Sector Weight
1 Healthcare 60.64%
2 Miscellaneous 18.13%
3 Financials 17.98%
4 Real Estate 1.4%
5 Utilities 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SBBP
1
DELISTED
Strongbridge Biopharma plc.
SBBP
$30.5M 28.22%
6,294,789
+896,755
+17% +$4.59M
LITS
2
Lite Strategy Inc
LITS
$38.8M
$15.9M 14.66%
183,930
-36,092
-16% -$2.95M
SPY icon
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$815B
$14.9M 13.78%
51,279
-658,821
-93% -$188M
GARS
4
DELISTED
Garrison Capital Inc.
GARS
$9.21M 8.52%
1,112,517
-6,012
-0.5% -$50.5K
MTEM
5
DELISTED
Molecular Templates, Inc.
MTEM
$8.62M 7.97%
106,616
+36,364
+52% +$2.79M
ICMB icon
6
Investcorp Credit Management BDC
ICMB
$12.8M
$7.7M 7.12%
901,439
+7,001
+0.8% +$62.7K
SCYX icon
7
SCYNEXIS
SCYX
$52.7M
$5.19M 4.8%
54,063
+17,125
+46% +$2.02M
AMLP icon
8
Alerian MLP ETF
AMLP
$13.5B
$4.47M 4.13%
83,683
-138
-0.2% -$7.44K
BRK.B icon
9
Berkshire Hathaway Class B
BRK.B
$1.08T
$1.99M 1.84%
9,312
– –
JBGS
10
JBG SMITH
JBGS
$685M
$1.52M 1.4%
41,170
– –
PCG icon
11
PG&E
PCG
$31.5B
$1.03M 0.96%
22,500
– –
UHAL icon
12
U-Haul Holding Co
UHAL
$13.1B
$963K 0.89%
27,000
– –
MRKR icon
13
Marker Therapeutics
MRKR
$19.7M
$738K 0.68%
8,154
-313
-4% -$26.9K
KURA icon
14
Kura Oncology
KURA
$1.18B
$607K 0.56%
34,708
+18,293
+111% +$351K
ACRS icon
15
Aclaris Therapeutics
ACRS
$908M
$577K 0.53%
39,755
+20,241
+104% +$347K
ARQL
16
DELISTED
Arqule Inc
ARQL
$511K 0.47%
90,254
+77,295
+596% +$440K
KALA icon
17
KALA BIO
KALA
$9.81M
$506K 0.47%
+21
New +$640K
CTIC
18
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$427K 0.39%
+197,459
New +$489K
INDP icon
19
Indaptus Therapeutics
INDP
$163M
$364K 0.34%
29
– –
ABDC
20
DELISTED
Alcentra Capital Corp
ABDC
$345K 0.32%
57,677
+2,318
+4% +$14.5K
EIGR
21
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$306K 0.28%
+850
New +$291K
CPRX
22
DELISTED
Catalyst Pharmaceutical
CPRX
$276K 0.26%
72,967
+39,166
+116% +$123K
FSTX
23
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$253K 0.23%
+5,247
New +$263K
FPAC.U
24
DELISTED
Far Point Acquisition Corporation Units, each consisting of one share of Class A common stock, $0.00
FPAC.U
$237K 0.22%
23,030
+926
+4% +$9.44K
DRNA
25
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$225K 0.21%
+14,724
New +$214K
1
2

Similar funds

1IC
1922 Investment Company Houston, Texas $1.89M AUM 15.39% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $1.91M AUM 81.42% 1-Year Est. Return
HGCK
HPC Germany & Co KG Potsdam, Germany $1.68M AUM 15.3% 1-Year Est. Return
CA
Cohalo Advisory Snoqualmie, Washington $1.65M AUM 11.44% 1-Year Est. Return
CAM
Creekmur Asset Management Morton, Illinois $2.07M AUM
FLC
Fifth Lane Capital Austin, Texas $1.63M AUM 7.3% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $1.56M AUM 25.68% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $2.18M AUM 50.81% 1-Year Est. Return

Caxton Corporation's Q3 2018 Portfolio in Review

As of Q3 2018, Caxton Corporation held 31 positions worth $108M, down 62% from $283M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Caxton Corporation deployed $9.09M of net new capital in Q3 2018, opening 6 new positions and adding to 13 existing holdings. Its largest new stake was KALA BIO: 21 shares worth $506K.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 22% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Lite Strategy Inc, an estimated $2.95M trimmed.

  • Caxton Corporation's largest Q3 2018 buy was KALA BIO: 21 shares worth $506K.
  • Caxton Corporation added most to Strongbridge Biopharma plc. in Q3 2018, an estimated $4.59M increase.
  • Caxton Corporation's biggest Q3 2018 reduction was Lite Strategy Inc, cutting an estimated $2.95M.
  • Caxton Corporation fully exited Oncternal Therapeutics, Inc. Common Stock in Q3 2018, selling an estimated $763K.
  • Caxton Corporation's ten largest holdings make up 92% of its $108M portfolio in Q3 2018.
  • Caxton Corporation opened 6 new positions and closed 2 in Q3 2018.
  • Caxton Corporation's portfolio value fell 62% quarter-over-quarter to $108M.

Based on Caxton Corporation's 13F filing for Q3 2018, filed 14 Nov 2018.